Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 27, 2020
Daily News
February 27, 2020
- Daiichi Sankyo’s Enhertu Clears MHLW Panel, Conditional Nod Expected in March
February 27, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Rust in Needles in Sanofi’s ActHIB “Occurred Accidentally,” Supplies to Resume: MHLW
February 27, 2020
- Zolgensma Now in Line for Japan Approval in March, All Eyes Now Riveted on Price
February 27, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
- Keytruda No. 1 Drug Prescribed at Acute-Care Hospitals in 2019: Survey
February 27, 2020
- AbbVie Files Humira for Pyoderma Gangrenosum in Japan
February 27, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…